{"filings":[{"id":1388036,"accession_number":"0001501697-26-000060","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2026-07-01T20:13:51+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"X4 Pharmaceuticals appoints Kelly Gold to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kelly Gold appointed as Class II director effective July 1, 2026; board expands from 5 to 6 members.","Gold is CFO of CAMP4 Therapeutics (Nasdaq: CAMP) and will serve on Audit Committee.","Gold brings financial leadership, capital markets expertise, and rare disease experience from Biogen.","No arrangements or family relationships with other directors/officers; standard compensation per non-employee director policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":70201,"accession_number":"0001501697-26-000051","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K/A","filed_at":"2026-05-13T20:57:53+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"X4 Pharma amends 8-K to correct director nominee; shareholders approve 1.5M share increase in equity plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended 8-K corrects nominee: Murray W. Stewart (not Michael S. Wyzga) elected as Class III director for 2029 term.","Elected directors: Gary J. Bridger, Françoise De Craecker, Murray W. Stewart; each received >71M votes for, ~6.5M broker non-votes.","Stockholders approved Second Amended and Restated 2017 Equity Incentive Plan, adding 1,500,000 shares (58.7M for, 17.7M against).","Ratified PricewaterhouseCoopers as auditor for FY2026 (82.7M for, 69K against).","Non-binding say-on-pay approved with 70.9M for, 5.4M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40883,"accession_number":"0001501697-26-000047","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2026-05-12T20:21:32+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"X4 Pharma shareholders approve 1.5M share equity plan increase, elect three directors at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved 1,500,000 additional shares under Second Amended and Restated 2017 Equity Incentive Plan.","Elected Gary Bridger, Françoise De Craecker, and Michael Wyzga as Class III directors until 2029.","Ratified PricewaterhouseCoopers as independent auditor for fiscal year ending Dec 31, 2026.","Say-on-pay advisory vote passed with 70.9 million for, 5.4 million against (excluding broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120974,"accession_number":"0001501697-25-000041","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"X4 Pharma Q3 net loss $29.8M ($0.69/sh); cash runway to end 2028 after $240.3M financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net product sales XOLREMDI $1.6M vs $0.6M YoY; net loss $0.69/sh vs $5.48/sh in Q3 2024.","Raised $240.3M gross via public offering and upsized private placement; cash runway extended to end of 2028.","50% workforce reduction yields ~$13M annualized cost savings; focus on Phase 3 4WARD chronic neutropenia trial.","Enrollment target for 4WARD increased to 176 patients; expected completion Q3 2026; sNDA potential in chronic neutropenia.","Deprioritized XOLREMDI commercialization for WHIM syndrome; John Volpone promoted to COO."],"consensus_eps_estimate":-0.9343,"consensus_eps_actual":-2.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":4300000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120973,"accession_number":"0001501697-25-000032","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"X4 Pharmaceuticals raises ~$145.6M in public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 45.86M shares at $2.90/share and pre-funded warrants for 700K shares at $2.899/share.","Underwriters' option for additional 6.984M shares exercised in full.","Net proceeds expected ~$145.6M after discounts and expenses; closing October 27, 2025.","Offered under effective shelf registration (333-273961); Leerink, Stifel, Guggenheim as representatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137576,"accession_number":"0001501697-25-000021","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["2.05","5.02","7.01","9.01"],"status":"ready","headline":"X4 Pharma cuts workforce 50%, saves ~$13M/yr; appoints new COO, execs depart","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~50%, expected to generate ~$13M in annualized cost savings.","Cash charges of ~$3.3M for severance and termination-related costs; substantially complete in Q3 2025.","COO Mary DiBiase, CCO Mark Baldry, CLO Natasha Thoren terminated; CMO Christophe Arbet-Engels resigns.","John Volpone appointed COO in addition to his role as President; Executive Chairman Adam Craig oversees clinical development.","Restructuring aims to focus resources on completing the 4WARD Phase 3 trial for chronic neutropenia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137575,"accession_number":"0001501697-25-000008","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"X4 Pharmaceuticals board members McGirr and Woods resign; audit committee reconstituted","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David McGirr and R. Keith Woods resigned from the board effective August 22, 2025, with no disagreement.","Michael Wyzga appointed as chair of the audit committee.","Francoise de Craecker and Gary Bridger appointed as members of the audit committee.","Resignations cover all committees; departure not related to operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137574,"accession_number":"0001501697-25-000006","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"X4 Pharmaceuticals closes upsized $85M private placement for mavorixafor development and WHIM commercialization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private placement of 11,040,776 shares and 48,852,772 pre-funded warrants for gross proceeds of $85M.","Purchase price per pre-funded warrant is $1.419; exercise price is $0.001 per share; warrants have no expiration.","Offering upsized from $60M due to pre-existing investment right from one investor; led by Coastlands Capital with support from existing investors.","Net proceeds to be used for continued development of mavorixafor for chronic neutropenia and commercialization of WHIM.","Shares and underlying shares to be registered for resale via an SEC registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137573,"accession_number":"0001628280-25-039770","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["1.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"X4 Pharma raises $60M, CEO and CFO resign, new leadership team appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 11,040,776 shares at $1.42/share and pre-funded warrants for 31,234,731 shares for ~$60M gross.","CEO Paula Ragan, Ph.D., and CFO Adam S. Mostafa resigned effective Aug 12, 2025; no disagreement cited.","Adam Raymond Craig, M.D., Ph.D., appointed Executive Chairman and principal executive officer; John Volpone named President.","David H. Kirske appointed CFO, Secretary, principal financial and accounting officer.","Proceeds to fund continued development of mavorixafor for chronic neutropenia and commercialization for WHIM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154937,"accession_number":"0001628280-25-032627","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"X4 Pharmaceuticals secures $40M equity line with Lincoln Park Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company may sell up to $40M of common stock to Lincoln Park over 24 months.","Purchase price set at 97% of the lower of lowest or 3-day-average closing price.","Regular purchases capped at 30k–60k shares per day based on stock price thresholds.","Issued 137,099 commitment shares to Lincoln Park as a fee for entering the agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154936,"accession_number":"0001628280-25-030743","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"X4 Pharmaceuticals stockholders elect R. Keith Woods as director, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["R. Keith Woods elected with 52.2M for, 29.9M withheld; 53.8M broker non-votes.","Ratification of PwC as auditor: 128.9M for, 6.6M against, 0.4M abstain.","Non-binding say-on-pay approved: 67.8M for, 12.2M against, 2.0M abstain, 53.8M broker non-votes.","All three proposals passed at annual meeting held June 9, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154935,"accession_number":"0001628280-25-021304","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"X4 Pharma Q1 net income $0.3M on $28.8M revenue; XOLREMDI sales $3.5M since launch; 4WARD trial on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net income $0.3M vs loss $51.8M YoY; revenue $28.8M included $27.9M license fee from Norgine.","XOLREMDI cumulative U.S. net sales $3.5M since May 2024 launch through March 2025.","Phase 3 4WARD CN trial full enrollment expected 3Q/4Q 2025; top-line data in 2H 2026.","Strategic restructuring to cut annual spending by $30-35M; cash $87.7M funds ops into 1H 2026.","Completed 1-for-30 reverse stock split effective April 28, 2025; shares reduced from ~173.6M to ~5.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":900000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154934,"accession_number":"0001628280-25-019507","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"X4 Pharmaceuticals announces 1-for-30 reverse stock split effective April 28 to regain Nasdaq bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-30 ratio effective 12:01 a.m. ET on April 28, 2025; shares trade split-adjusted under XFOR.","Outstanding shares reduced from ~173.6M to ~5.8M; no fractional shares issued, cash in lieu.","Split intended to cure Nasdaq minimum bid price deficiency; company received extension to August 11, 2025.","Proportional adjustments made to equity awards, options, and warrants; CUSIP changes to 98420X202."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154933,"accession_number":"0001628280-25-018389","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"X4 Pharma stockholders approve reverse stock split; ratio 1:15 to 1:30 to be set by board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting held April 17, 2025; ~79% of outstanding shares (137.2M of 173.7M) present, forming quorum.","Reverse split approved: 113.0M FOR, 24.0M AGAINST, 224k abstentions; no broker non-votes.","Amendment authorizes board to set exact ratio between 1-for-15 and 1-for-30.","Related Proposal 2 was not presented because Proposal 1 passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173457,"accession_number":"0001628280-25-014601","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"X4 Pharma FY2024 net rev $2.6M; Phase 3 CN trial on track; restructuring cuts spend $30-35M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["XOLREMDI net product revenue $2.6M from May 2024 launch through YE; cost of revenue $0.8M.","Net loss FY2024 $37.5M (incl. $105M PRV gain); cash $102.8M; pro-forma runway into 1H 2026.","Phase 3 4WARD trial for chronic neutropenia activated at ~90% sites; full enrollment expected Q3/Q4 2025; top-line data 2H 2026.","Protocol amendment: enroll only moderate/severe CN (ANC<1000); co-primary endpoint refined to uniform ANC increase ≥500 cells/µL.","Strategic restructuring reduces annual spend by $30-35M; includes headcount reduction, closing Vienna facility, and right-sizing US team."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173456,"accession_number":"0001628280-25-009490","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"X4 Pharmaceuticals gets second Nasdaq compliance period until Aug 11, 2025 for bid price rule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closing bid price of XFOR common stock below $1 for 32 consecutive business days as of Aug 13, 2024.","Initial 180-day compliance period ended Feb 10, 2025; Nasdaq granted additional 180 days to Aug 11, 2025.","Company may effect a reverse stock split to regain compliance if necessary.","Failure to comply by Aug 11, 2025 may lead to delisting and an appeal process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173455,"accession_number":"0001628280-25-004254","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"X4 Pharmaceuticals cuts 30% of workforce, closes Vienna facility, expects $30-35M annual savings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Headcount reduced by 43 (~30%); Vienna facility closed; preclinical programs paused.","Estimated $3.0M in severance charges, primarily in Q1 2025.","Annual spending expected to decrease by $30-35M; cash runway into first half 2026.","Phase 3 trial for mavorixafor in chronic neutropenia enrollment on track for mid-2025.","Focus on advancing mavorixafor for chronic neutropenia and optimizing XOLREMDI promotion for WHIM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173454,"accession_number":"0001628280-25-001239","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"X4 Pharma licenses mavorixafor to Norgine for €28.5M upfront, up to €226M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exclusive license for Europe, Switzerland, UK, Australia, New Zealand; X4 retains rest of world.","X4 receives €28.5M upfront; up to €226M in regulatory, commercial, sales milestones.","Escalating double-digit royalties up to mid-twenties on net sales in licensed territories.","X4 continues Phase 3 4WARD trial in chronic neutropenia; Norgine handles commercialization.","MAA for WHIM syndrome to be submitted to EMA shortly; mavorixafor has Orphan Drug Designation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190442,"accession_number":"0001628280-24-047433","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"X4 reports positive Phase 2 mavorixafor data: ANC normalized, G-CSF reduced 70% in chronic neutropenia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mavorixafor monotherapy durably increased mean ANC to normal levels at Month 3 (n=9) and Month 6 (n=8).","Severe CN patients achieved >2-fold mean ANC increase over 6 months (n=4).","G-CSF dose reduced in 9/12 eligible patients; mean reduction 52% at Month 3, 70% at Month 6 with normal ANC.","Neutrophil functionality sub-study: mean % functional neutrophils comparable to healthy donors after 6 months.","No drug-related serious adverse events; mavorixafor generally well tolerated as monotherapy and combination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190441,"accession_number":"0001628280-24-047406","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"X4 Pharma Q3 net loss $36.7M; positive Phase 2 CN data; XOLREMDI launch underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $36.7M vs $2.3M loss in Q3 2023; includes $1.9M non-cash loss on warrant liability.","Net product revenue of $0.6M from XOLREMDI (mavorixafor) for WHIM syndrome, launched April 2024.","Positive Phase 2 results: mavorixafor durably increased absolute neutrophil counts and enabled G-CSF reduction in chronic neutropenia.","Phase 3 4WARD trial on track to fully enroll mid-2025; regulatory approvals in ~85% of targeted countries.","Cash $135.8M, sufficient into late 2025 (excludes potential XOLREMDI revenue)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":1123000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206945,"accession_number":"0001628280-24-037546","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"X4 Pharmaceuticals receives Nasdaq deficiency notice for minimum bid price rule; 180 days to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Aug 13, 2024, Nasdaq notified X4 that its common stock closing bid price was below $1.00 for 32 consecutive business days.","Company has until Feb 10, 2025 to regain compliance by closing at $1.00+ for ten consecutive days.","If not compliant by Feb 10, X4 may be eligible for additional 180-day cure period if it meets other listing standards.","X4 says it will monitor bid price and consider options including a reverse stock split to cure deficiency.","There is no immediate delisting; stock continues trading under symbol XFOR on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206944,"accession_number":"0001628280-24-036495","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"X4 Pharmaceuticals posts updated corporate presentation on website","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation posted on August 8, 2024, in Investors section of www.x4pharma.com.","No financial results, guidance, or material business updates disclosed in filing.","Presentation content not filed with SEC; furnished under Regulation FD.","Investors directed to company website for details; no exhibit included in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206943,"accession_number":"0001628280-24-035848","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"X4 reports Q2 net income $90.8M on PRV sale; first XOLREMDI sales $0.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net income $90.8M vs net loss $55.7M YoY; includes $105M gain on sale of priority review voucher.","First product revenue $0.6M from XOLREMDI launch following FDA approval in April 2024 for WHIM syndrome.","Cash, equivalents, marketable securities $169.5M; operating runway into late 2025 (excl. future revenue).","Positive interim Phase 2 data for mavorixafor in chronic neutropenia; full results expected Nov 2024; Phase 3 4WARD trial started.","Plans to submit EMA approval for mavorixafor in WHIM syndrome by early 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":563000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206942,"accession_number":"0001628280-24-032266","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"X4 Pharmaceuticals updates corporate presentation; no material new details provided","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Posted updated corporate presentation on company website on July 19, 2024.","Presentation available in Investors section of www.x4pharma.com.","No specific financial or operational updates disclosed in the 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224227,"accession_number":"0001628280-24-030243","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"X4 reports positive Phase 2 mavorixafor data in chronic neutropenia; starts Phase 3 4WARD trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% (6/6) evaluable participants achieved target ANC increase (>500 cells/µL) at Months 3 and 6 on mavorixafor ± G-CSF.","Mavorixafor monotherapy achieved mean ANC ≥1,500 cells/µL at Months 3 and 6; severe CN patients had mean ANC ~800-1,000 cells/µL.","Combination with stable-dose G-CSF increased mean ANC >1,000 cells/µL vs baseline at Months 1, 3, and 6.","No drug-related serious adverse events; three discontinuations due to non-serious AEs.","Global Phase 3 4WARD trial initiated (randomized, 150 patients, 52 weeks) for congenital, autoimmune, or idiopathic CN."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224226,"accession_number":"0001628280-24-027680","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"X4 Pharmaceuticals annual meeting elects directors, ratifies auditor, approves say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected David McGirr, Paula Ragan, and Michael S. Wzyga as directors for three-year terms.","Ratification of PricewaterhouseCoopers LLP as independent auditor for FY 2024 passed with 129,116,244 for, 620,394 against.","Non-binding say-on-pay vote approved with 89,159,259 for, 4,443,024 against, and 36,561,395 broker non-votes.","All three proposals received requisite majority support; no other matters were submitted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224225,"accession_number":"0001628280-24-024633","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"X4 Pharmaceuticals files corporate presentation with no specific material updates provided","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing includes a corporate presentation dated May 22, 2024, but full content not available for analysis.","No new financial or clinical data points are discernible from the limited exhibit excerpt.","The presentation appears to be a routine investor deck; no actionable events reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224224,"accession_number":"0001628280-24-021937","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["1.01","2.01","5.02","7.01","8.01","9.01"],"status":"ready","headline":"X4 Pharma sells PRV for $105M, draws $20M from Hercules; cash runway extended into late 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold Rare Pediatric Disease Priority Review Voucher for $105M cash; buyer undisclosed.","Drew additional $20M tranche under existing Hercules Capital term loan facility (interest-only until July 2027).","Combined with $82M cash at March 31, 2024, total pro-forma cash ~$207M; runway extended into late 2025, excluding XOLREMDI sales.","CFO Adam Mostafa awarded $102K discretionary bonus for efforts in securing the PRV sale.","XOLREMDI (mavorixafor) received FDA approval in April 2024 for WHIM syndrome; Phase 3 trial in chronic neutropenia planned this quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224223,"accession_number":"0001628280-24-020827","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"X4 Pharma reports Q1 net loss of $51.8M; XOLREMDI approved for WHIM syndrome","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $51.8M vs $24.0M in Q1 2023; includes $13.8M non-cash loss on warrant liability.","Cash, equivalents, and securities $81.6M as of Mar 31, 2024; runway into 2025 excluding PRV monetization.","FDA approved XOLREMDI (mavorixafor) for WHIM syndrome in patients 12+ in late April 2024; U.S. launch underway.","Phase 2 interim data for mavorixafor in chronic neutropenia expected June 2024; Phase 3 trial planned in Q2 2024.","SG&A expenses rose to $17.4M from $7.2M due to commercial launch preparations."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224222,"accession_number":"0001628280-24-018793","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA approves X4 Pharma's XOLREMDI for WHIM syndrome; pricing set at $496,400/yr","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["XOLREMDI (mavorixafor) approved for WHIM syndrome patients aged 12+ to increase neutrophils and lymphocytes.","Wholesale acquisition cost: $496,400/yr (patients >50 kg, 400 mg daily) and $372,300/yr (≤50 kg, 300 mg daily).","Launch through specialty pharmacy PANTHERx Rare; X4Connect support program offers copay assistance and insurance help.","Corporate presentation posted on company website providing business updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224221,"accession_number":"0001628280-24-018773","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"X4 Pharma receives FDA approval for XOLREMDI (mavorixafor), first drug for WHIM syndrome","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["XOLREMDI approved for patients 12+ with WHIM syndrome to increase circulating neutrophils and lymphocytes.","Phase 3 4WHIM trial met primary endpoint (TAT-ANC) vs. placebo (p<0.0001).","XOLREMDI showed 60% reduction in annualized infection rate vs. placebo.","X4 granted Rare Pediatric Disease Priority Review Voucher concurrent with approval.","U.S. commercial launch via specialty pharmacy PANTHERx Rare; X4Connect patient support launched."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224220,"accession_number":"0001628280-24-015059","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"X4 Pharmaceuticals regains Nasdaq bid price compliance; deficiency notice closed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq deficiency notice on Nov 13, 2023 for bid price below $1.00 for 30 consecutive trading days.","On April 5, 2024, Nasdaq confirmed compliance with Bid Price Rule; matter now closed.","Common stock (XFOR) remains listed on The Nasdaq Stock Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224219,"accession_number":"0001628280-24-013896","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"X4 Pharmaceuticals posts updated corporate presentation on website","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["X4 Pharmaceuticals filed an 8-K on April 1, 2024, announcing an updated corporate presentation.","The presentation is available on the Investors section of the company's website at www.x4pharma.com.","No financial results, material agreements, or other major events were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243570,"accession_number":"0001628280-24-012372","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"X4 Pharma reports FY2023 net loss $101.2M; cash $115.2M; PDUFA for WHIM syndrome April 30","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.1M Q4 and $101.2M FY2023; R&D $15.3M Q4 and $72.0M FY2023; SG&A $9.9M Q4 and $35.5M FY2023.","Cash, equivalents, restricted cash and marketable securities of $115.2M at Dec 31, 2023; runway into 2025.","FDA PDUFA target action date April 30, 2024 for mavorixafor in WHIM syndrome; launch preparations underway.","Additional Phase 2 results and global Phase 3 trial initiation for chronic neutropenia expected in 1H24.","No guidance change; projected runway excludes debt drawdowns or potential Priority Review Voucher monetization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243569,"accession_number":"0001628280-24-000843","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"X4 Pharmaceuticals posts updated corporate presentation on website; no specific details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated corporate presentation posted on January 8, 2024, in the Investors section of www.x4pharma.com.","No financial or operational metrics, guidance, or material events provided in the filing.","Presentation content not appended; investors must access directly from the company website.","Filing is a Regulation FD disclosure; information is furnished, not filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260983,"accession_number":"0001628280-23-040050","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2023-11-27T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"X4 Pharmaceuticals posts updated corporate presentation; no specific financial details provided","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["X4 Pharmaceuticals posted an updated corporate presentation on its website on November 27, 2023.","Presentation available in the 'Investors' section of www.x4pharma.com.","No further details from the presentation were disclosed in the 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260982,"accession_number":"0001628280-23-038936","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"X4 Pharmaceuticals receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Nov 13, 2023 for non-compliance with minimum $1.00 bid price rule.","Common stock closing bid price below $1.00 for 30 consecutive business days.","Company has 180 calendar days, until May 13, 2024, to regain compliance.","If not compliant by deadline, may request additional 180 days if other listing standards are met.","Considering potential reverse stock split to cure deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260981,"accession_number":"0001628280-23-038053","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"X4 Pharma: NDA accepted for mavorixafor in WHIM with PDUFA April 30, 2024; Q3 net loss $2.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA accepted NDA for once-daily oral mavorixafor in WHIM syndrome with Priority Review; PDUFA target April 30, 2024; eligible for Priority Review Voucher if approved.","Ongoing Phase 2 chronic neutropenia data to be presented at ASH Dec 9-12, 2023; Phase 3 trial initiation expected 1H 2024.","Q3 2023 cash, equivalents, and marketable securities totaled $142.7M; net loss of $2.3M (incl. $25.2M non-cash gain vs. $21.6M net loss in Q3 2022).","Completed $115M debt facility with Hercules Capital; initial draw of $22.5M in August 2023.","Appointed Christophe Arbet-Engels, MD, PhD as Chief Medical Officer in August 2023; added R. Keith Woods to Board of Directors in October 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260980,"accession_number":"0001628280-23-035729","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA accepts X4's NDA for mavorixafor with Priority Review; PDUFA April 30, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted NDA for once-daily oral mavorixafor in WHIM syndrome (ages 12+) with Priority Review.","PDUFA target action date set for April 30, 2024; six-month review timeline.","If approved, X4 eligible for Priority Review Voucher due to rare pediatric disease designation.","NDA supported by Phase 3 4WHIM trial meeting primary endpoint (TAT-ANC p<0.0001) and reducing infections.","No approved therapies for WHIM syndrome; mavorixafor has Breakthrough Therapy, Fast Track, and Orphan status."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260979,"accession_number":"0001628280-23-034547","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2023-10-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"X4 Pharmaceuticals appoints industry veteran R. Keith Woods to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Woods appointed as independent Class II director effective Oct 16, 2023, term through 2025 annual meeting.","He brings 30+ years life science experience, most recently COO of argenx, leading rare disease global launch.","Received initial equity award of 90,000 RSUs vesting equally over 3 years; accelerated on change of control.","No family relationships or material interests with directors/officers; standard indemnification agreement entered.","Appointment follows recent U.S. regulatory submission of X4's first drug candidate (mavorixafor) for WHIM syndrome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278249,"accession_number":"0001628280-23-031405","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2023-09-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"X4 Pharma submits NDA to FDA for mavorixafor in WHIM syndrome","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submission supported by positive Phase 3 4WHIM trial results; met primary and key secondary endpoints.","Requested priority review; if granted, FDA review period would be six months from acceptance.","Mavorixafor is an oral once-daily candidate for WHIM syndrome, a rare primary immunodeficiency in patients 12+.","No treatment-related serious adverse events or discontinuations for safety in the Phase 3 trial.","CEO Paula Ragan calls it a significant milestone; could be first approved U.S. product for WHIM syndrome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278248,"accession_number":"0001628280-23-028730","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"X4 Pharma Q2 net loss $55.7M; WHIM NDA on track; chronic neutropenia data promising","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $55.7M in Q2 2023 includes $29.9M non-cash warrant adjustment; cash $142.3M at June 30.","NDA submission for mavorixafor in WHIM syndrome on track for early 2H 2023; potential US approval in 1H 2024.","Preliminary Phase 2 chronic neutropenia data: mavorixafor increased ANC and enabled G-CSF dose reductions in 3 patients.","Raised ~$65M via PIPE in May 2023; post-quarter expanded debt facility to $115M with $22.5M initial drawdown.","Appointed Dr. Christophe Arbet-Engels as Chief Medical Officer; new mavorixafor composition-of-matter patent through 2038."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278247,"accession_number":"0001628280-23-027303","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"X4 Pharmaceuticals closes $115M loan facility with Hercules Capital; draws $22.5M initially","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $115M term loan facility with Hercules Capital; $32.5M refinanced, $22.5M drawn at closing.","Additional tranches: up to $20M post-US approval of mavorixafor, $7.5M on clinical milestone, $32.5M subject to lender approval.","Interest-only payments through March 2025 at variable rate (greater of 10.15% or 3.15%+prime); maturity Oct 2026, extendable to July 2027.","Cash covenant: maintain qualified cash at least $20M pre-Jan 2025, then 20% of loans outstanding.","Proceeds extend cash runway into 2025; support commercial launch prep for mavorixafor in WHIM syndrome and chronic neutropenic disorders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296358,"accession_number":"0001628280-23-022266","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"X4 Pharmaceuticals stockholders elect three directors and approve all proposals at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Gary J. Bridger, Francoise de Craecker, and Murray W. Stewart as directors for three-year terms.","Ratified PricewaterhouseCoopers LLP as independent auditor for FY2023 with 94.3M votes for.","Advisory vote on named executive officer compensation approved with 59.3M for vs 8.0M against.","Stockholders preferred a one-year frequency for future say-on-pay votes; board adopted annual votes.","Approved Amended and Restated 2017 Employee Stock Purchase Plan with 66.7M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296357,"accession_number":"0001628280-23-020502","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2023-06-01T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"X4 Pharmaceuticals posts updated corporate presentation to website","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing indicates an updated corporate presentation was made available on the company's website.","No specific financial data, milestones, or material events are disclosed in the 8-K.","Investors are directed to the Investors section of x4pharma.com for the presentation content."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296356,"accession_number":"0001628280-23-018424","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"X4 Pharma announces $65M PIPE and positive Phase 3 mavorixafor data in WHIM syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["42.8M shares/pre-funded warrants priced at $1.52, raising $65M gross; expected close May 18, 2023.","Phase 3 4WHIM trial: mavorixafor reduced annualized infection rate by ~60% vs placebo (p<0.01).","Severe (Grade≥3) infections cut by 75%; mean infection duration reduced >70% (2 weeks vs 7 weeks on placebo).","NDA submission for mavorixafor in WHIM syndrome on track for early 2H 2023 after pre-NDA meeting with FDA.","Cash runway extended into Q4 2024, excluding potential priority review voucher proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296355,"accession_number":"0001628280-23-015714","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"X4 Pharmaceuticals posts updated corporate presentation on its website","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation posted May 4, 2023 on X4 Pharma's investor website.","No specific financial, clinical, or operational updates disclosed in the filing.","Presentation content and changes not detailed; investors directed to website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296354,"accession_number":"0001628280-23-015494","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"X4 Pharma Q1 net loss $24M; cash $94.4M funds ops into Q2 2024; WHIM NDA on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and restricted cash of $94.4M as of March 31, 2023, sufficient into Q2 2024.","R&D expenses $22.1M (up from $14.1M YoY) including $5.0M accrual for probable in-licensing milestone.","Net loss $24.0M vs $22.0M YoY; includes $1.6M stock compensation and $5.4M gain on warrant liability.","U.S. NDA submission for mavorixafor in WHIM syndrome on track for early second half 2023.","Phase 2 chronic neutropenia data and regulatory path update anticipated in Q2/Q3 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296353,"accession_number":"0001628280-23-015415","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"X4 Pharma Q1 net loss $24.0M; cash $94.4M into Q2 2024; mavorixafor NDA on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.0M in Q1 2023 vs $22.0M in Q1 2022; R&D expenses $22.1M including $5.0M milestone accrual.","Cash, equivalents & restricted cash $94.4M as of March 31, 2023; sufficient to fund operations into Q2 2024.","U.S. NDA submission for mavorixafor in WHIM syndrome on track for early second half of 2023.","Phase 3 WHIM trial infection data to be presented at May 16 webinar and May 21 CIS oral presentation.","Phase 2 chronic neutropenia trial data and regulatory path clarity expected in Q2/Q3 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316838,"accession_number":"0001628280-23-008761","cik":1501697,"company_name":"X4 Pharmaceuticals, Inc","ticker":"XFOR","form_type":"8-K","filed_at":"2023-03-21T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"X4 Pharmaceuticals posts updated corporate presentation; no specifics disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated corporate presentation posted to company website on March 21, 2023, but contents not provided in filing.","Investors directed to www.x4pharma.com to view the presentation.","No financial results, pipeline updates, or guidance changes disclosed in the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":343320000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-03-21T23:59:59+00:00|316838"}